Globus Medical EVP sells 10,000 shares under plan

Globus Medical executive Kelly Huller, EVP, General Counsel and Corporate Secretary, reported an option exercise and share sale.

Rhea-AI Filing Summary

Globus Medical executive Kelly Huller, EVP, General Counsel and Corporate Secretary, reported an option exercise and share sale. On February 12, 2026, she exercised stock options for 10,000 Class A shares at $45.64 per share, converting a fully vested grant from February 2018.

The same day, she sold 10,000 Class A shares at $87.67 per share in an open-market transaction, leaving her with 0 directly owned shares and 0 remaining options from this grant. The sale was executed under a pre-arranged Rule 10b5-1 trading plan dated November 12, 2025.

Insider Trade Summary

Exercise and Sale: 10,000 shares ($420K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Huller Kelly

Role EVP, GC, Corporate Secretary

Sold 10,000 shs ($877K)

Approx. gross sale proceeds $877K

Approx. exercise cost $456K

Approx. pre-tax spread $420K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy Class A Common Stock)	10,000	$0.00	$0.00
Exercise	Class A Common Stock	10,000	$45.64	$456K
Sale	Class A Common Stock	10,000	$87.67	$877K

Holdings After Transaction: Stock Option (Right to Buy Class A Common Stock) — 0 contracts (Direct); Class A Common Stock — 0 shares (Direct)

Footnotes (2)

1. F1. This sale was effectuated pursuant to a Rule 10b5-1 trading plan dated November 12, 2025 executed by the reporting person.
2. F2. These options were granted on February 2, 2018 and are fully vested.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Globus Medical (GMED) report for Kelly Huller?

Globus Medical reported that EVP and General Counsel Kelly Huller exercised options for 10,000 Class A shares and sold 10,000 shares on February 12, 2026, according to a Form 4 insider trading report filed under Section 16 rules.

How many Globus Medical (GMED) shares did Kelly Huller sell and at what price?

Kelly Huller sold 10,000 shares of Globus Medical Class A common stock at an average price of $87.67 per share. The transaction was an open-market sale disclosed in the Form 4 insider report for February 12, 2026.

What stock options did Kelly Huller exercise at Globus Medical (GMED)?

She exercised a stock option for 10,000 shares of Globus Medical Class A common stock at an exercise price of $45.64 per share. These options were granted on February 2, 2018 and were fully vested at the time of exercise.

Does Kelly Huller still directly own Globus Medical (GMED) shares after this Form 4?

Following the reported transactions, Kelly Huller directly owned 0 shares of Globus Medical Class A common stock. The Form 4 shows 10,000 shares acquired via option exercise and 10,000 shares sold, leaving no directly held balance from this grant.

Was Kelly Huller’s Globus Medical (GMED) stock sale under a 10b5-1 plan?

Yes. The Form 4 footnote states the 10,000-share sale was executed under a Rule 10b5-1 trading plan dated November 12, 2025. Such plans allow pre-arranged trades following specific conditions, helping insiders diversify while managing regulatory constraints.

What is Kelly Huller’s role at Globus Medical (GMED) mentioned in the Form 4?

The filing identifies Kelly Huller as an officer of Globus Medical, serving as Executive Vice President, General Counsel, and Corporate Secretary. This makes her a Section 16 reporting person required to disclose option exercises and stock transactions in company shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 05:22 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Huller Kelly

(Last) (First) (Middle)

VALLEY FORGE BUSINESS CENTER

2560 GENERAL ARMISTEAD AVENUE

(Street)

AUDUBON PA 19403

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GLOBUS MEDICAL INC [ GMED ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, GC, Corporate Secretary

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/12/2026		M		10,000	A	$45.64	10,000	D
Class A Common Stock	02/12/2026		S(1)		10,000	D	$87.67	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy Class A Common Stock)	$45.64	02/12/2026		M			10,000	(2)	02/02/2028	Class A Common Stock	10,000	$0	0	D

Explanation of Responses:

1. This sale was effectuated pursuant to a Rule 10b5-1 trading plan dated November 12, 2025 executed by the reporting person.

2. These options were granted on February 2, 2018 and are fully vested.

	/s/ Kelly G. Huller	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.